FibroBiologics FBLG Q1 2026 Earnings Narrow EPS Miss as PreRevenue Biotech Continues RD Investment LWLG Q3 2024 Earnings Continued RD Investment as Revenue Yet to Materialize EPM Q1 2026 Earnings Significant EPS Miss Amid Challenging Quarter DOYU Q4 2025 Earnings Massive EPS Surprise as Company Returns to Profitability XOMAP Q1 2026 Earnings Preferred Stock Reports EPS Miss Amid Royalty Revenue Uncertainty Neuraxis Inc NRXS Q1 2026 Earnings Narrower Loss Beats Estimates but Stock Slips on PreRevenue Concerns